To study whether this positive resistance gene signature, including CYP24A1, DNAJC12, EREG, NPTX1, PAEP and TRPM8, could also be a predictor signature for drug resistance in other cancer types, we analyzed the pooled HRs of disease-free survival time for these resistance genes in colon cancer, renal carcinoma, gastric cancer and pancreatic cancer. This evidence concerns the gene DNAJC12 and malignant colon neoplasm.